



## **Centrexion Therapeutics to Present at 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference**

**BOSTON, Mass.**, January 5, 2018 – [Centrexion Therapeutics](http://www.centrexion.com), a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that Jeffrey B. Kindler, chief executive officer, will present at 3:00 p.m. PT on Tuesday, January 9, 2018 at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, CA.

### **About Centrexion Therapeutics**

Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.

For more information about Centrexion, visit <http://www.centrexion.com>.

###

### **IR Contact**

Courtney Dugan, Pure Communications, Inc.  
+1 (212) 257-6723  
[cdugan@purecommunications.com](mailto:cdugan@purecommunications.com)

### **Media Contact**

Julie Normart, Pure Communications, Inc.  
+1 (415) 946-1087  
[jnormart@purecommunications.com](mailto:jnormart@purecommunications.com)